27 August 2024 - JW Therapeutics announced that the National Medical Products Administration of China has approved the supplemental Biological License Application for its anti-CD19 autologous chimeric antigen receptor T-cell immunotherapy product Carteyva (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed or refractory Mantle cell lymphoma. 

This is the third marketing approval on Carteyva submitted by JW Therapeutics, and is the first cell therapy product approved in China for the treatment of patients with relapsed or refractory Mantle cell lymphoma.

Read JW Therapeutics press release